Life Extension Final Clerance Sale

Life Extension Magazine

Life Extension Magazine June 2013
As We See It  

Dangerous Misconceptions

By William Faloon
Male and Female Blood Test Panels

Unlike commercial blood tests that evaluate only a few disease risk factors, Life Extension’s Male and Female Blood Test. Panels measure a wide range of blood markers that predispose people to common age-related disorders. This year we are able to add the hemoglobin A1c test to the Male and Female Panels at no additional cost. Hemoglobin A1c is a measurement of long-term glucose control. Just look at the huge number of parameters included in the Male and Female Blood Test Panels:

MALE PANEL FEMALE PANEL

Lipid Profile

Total Cholesterol
LDL (low-density lipoprotein)
HDL (high-density lipoprotein)
Triglycerides

Cardiac Markers

C-Reactive Protein (high sensitivity)
Homocysteine

Hormones

Free and Total Testosterone
DHEA-S
Estradiol (an estrogen)
TSH (thyroid function)
Vitamin D (25-hydroxyvitamin D)

Metabolic Profile

Glucose
Kidney function tests: creatinine, BUN, uric acid, BUN/creatinine ratio
Liver function tests: AST, ALT, LDH, GGT, bilirubin, alkaline phosphatase
Blood minerals: calcium, potassium, phosphorus, sodium, chloride, iron
Blood proteins: albumin, globulin, total protein, albumin/globulin ratio
Hemoglobin A1c (Now Includes HEMOGLOBIN A1c)

Complete Blood Count (CBC)

Red Blood Cell count including: hemoglobin, hematocrit, MCV, MCH, MCHC, RDW
White Blood Cell count including: lymphocytes, monocytes, eosinophils, neutrophils, basophils
Platelet count

Cancer Marker

PSA (Prostate Specific Antigen)

Lipid Profile

Total Cholesterol
LDL (low-density lipoprotein)
HDL (high-density lipoprotein)
Triglycerides

Cardiac Markers

C-Reactive Protein (high sensitivity)
Homocysteine

Hormones

Progesterone
DHEA-S
Free and Total Testosterone
Estradiol (an estrogen)
TSH (thyroid function)
Vitamin D (25-hydroxyvitamin D)

Metabolic Profile

Glucose
Kidney function tests: creatinine, BUN, uric acid, BUN/creatinine ratio
Liver function tests: AST, ALT, LDH, GGT, bilirubin, alkaline phosphatase
Blood minerals: calcium, potassium, phosphorus, sodium, chloride, iron
Blood proteins: albumin, globulin, total protein, albumin/globulin ratio
Hemoglobin A1c (Now Includes HEMOGLOBIN A1c)

Complete Blood Count (CBC)

Red Blood Cell count including: hemoglobin, hematocrit, MCV, MCH, MCHC, RDW
White Blood Cell count including:
lymphocytes, monocytes, eosinophils, neutrophils, basophils
Platelet count

Non-member retail price: $400 • Special Member Discount Price: $199. Blood Test Super Sale — April 1 through June 3, 2013.
To obtain these comprehensive Male or Female Panels at these low prices, call 1-800-208-3444 to order your requisition forms.
Then—at your convenience—you can visit one of the blood-drawing facilities provided by LabCorp in your area.
(Restrictions apply in NY, NJ, RI, MA, MD)

References

  1. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1695-8.
  2. Tohmé C, Labaki M, Hajj G, Abboud B, Noun R, Sarkis R. Colorectal cancer in young patients: presentation, clinicopathological characteristics and outcome. J Med Liban. 2008 Oct-Dec;56(4):208-14.
  3. O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003 Oct;69(10):866-72.
  4. Mitry E, Benhamiche AM, Jouve JL, Clinard F, Finn-Faivre C, Faivre J. Colorectal adenocarcinoma in patients under 45 years of age: comparison with older patients in a well-defined French population. Dis Colon Rectum. 2001 Mar;44(3):380-7.
  5. Available at: http://circ.ahajournals.org/content/109/5/558.full. Accessed February 4, 2013.
  6. Available at: http://www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ucm_319576.pdf. Accessed February 4, 2013.
  7. Available at: http://circ.ahajournals.org/content/121/7/e46.full.pdf. Accessed February 4, 2013.
  8. Montalcini T, Gorgone G, Federico D, et al. Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2005 Oct;15(5):368-72.
  9. LaRosa JC. Women, lipoproteins and cardiovascular disease risk. Can J Cardiol. 1990 May;6 Suppl B:23B-9B.
  10. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992 Jan-Mar;2(1-2):161-76.
  11. Kim HK, Kim CH, Kim EH, et al. Impaired fasting glucose and risk of cardiovascular disease in korean men and women: the korean heart study. Diabetes Care. 2013 Feb;36(2):328-35.
  12. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010 Mar 30;55(13):1310-7.
  13. Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000 Jun;71(6):1455-61.
  14. Levitzky YS, Pencina MJ, D’Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol. 2008 Jan 22;51(3):264-70.
  15. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18;298(3):309-16.
  16. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 Jul 18;298(3):299-308.
  17. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996 Apr;3(2):213-9.
  18. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ. 1993 Nov 20;307(6915):1318-22.
  19. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C- reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 Aug 25;98(8):731-3.
  20. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12): 836-43.
  21. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1668-73.
  22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65.
  23. Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol. 2003 Jul;18(4):286-94.
  24. Stensvold I, Urdal P, Thürmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, cardiovascular and all-cause mortality among middle-aged Norwegian men and women. Eur Heart J. 1992 Sep;13(9):1155-63.
  25. Mazza A, Tikhonoff V, Schiavon L, Casiglia E. Triglycerides +high-density-lipoprotein-cholesterol dyslipidaemia, a coronary risk factor in elderly women: the CArdiovascular STudy in the ELderly. Intern Med J. 2005 Oct;35(10): 604-10.
  26. Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL. Metabolic syndrome and vascular risk: a 9-year follow-up among the aged in Finland. Acta Diabetol. 2011 Jun;48(2):157-65.
  27. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989 Jan;79(1):8-15.
  28. Available at: http://www.mayoclinic.com/health/heart-disease/HB00040. Accessed January 2013.
  29. Tankó LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005 Apr 19;111(15):1883-90.
  30. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and javascript:void(0)insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003 Jan 28;107(3):448-54.
  31. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006 Mar;91(3):813-9.
  32. McSweeney JC, Cody M, O’Sullivan P, Elberson K, Moser DK, Garvin BJ. Women’s early warning symptoms of acute myocardial infarction. Circulation. 2003 Nov 25;108(21):2619-23.
  33. Akishita M, Hashimoto M, Ohike Y, et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors. Hypertens Res. 2008 Jan;31(1):69-74.
  34. Sablik Z, Samborska-Sablik A, Goch JH. Concentrations of adrenal steroids and sex hormones in postmenopausal women suffering from coronary artery disease. Pol Merkur Lekarski. 2008 Oct;25(148):326-9.
  35. Słowińska-Srzednicka J, Malczewska B, Srzednicki M, et al. Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. J Intern Med. 1995 May;237(5):465-72.
  36. Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. 2010 Nov;95(11):4985-92.
  37. Godoy-Matos AF, Vaisman F, Pedrosa AP, Farias ML, Mendonça LM, Pinheiro MF. Central-to-peripheral fat ratio, but not peripheral body fat, is related to insulin resistance and androgen markers in polycystic ovary syndrome. Gynecol Endocrinol. 2009 Dec;25(12):793-8.
  38. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.1993.tb01744.x/pdf. Accessed March 5, 2013.
  39. Glueck CJ, Goldenberg N, Wang P, Loftspring M, Sherman A. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod. 2004 Mar;19(3):510-21.
  40. Campagnoli C, Pasanisi P, Abbà C, et al. Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer. 2012 Jun;12(3):175-82.
  41. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer. 2008 Dec;8(6):501-5.
  42. Sir T, Castillo T, Munoz S, Lopez G, Calvillan M. Effects of metformin on insulin resistance in obese and hyperandrogenic women. Rev Med Chil. 1997 Dec;125(12):1457-63.
  43. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16(4):621-29.
  44. Velazquez EM, Mendosa S, Hamer T, Sosa F, Glucck CJ. Metformin therapy in women with polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating menstrual regularity and pregnancy. Metabolism. 1994 May;43(5):647-54.
  45. Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH. The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet. 2011 Jul;28(7):591-6.
  46. Available at: http://suite101.com/article/metformin-has-many-benefits-for-women-with-pcos-a146402. Accessed March 5, 2013.
  47. Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab. 2008 Apr;93(4):1276-84.
  48. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010 Jul-Aug;16(4):347-63.
  49. Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004 Feb;56(1):41-51.
  50. Carmina E. PCOS: metabolic impact and long-term management. Minerva Ginecol. 2012 Dec;64(6):501-6.
  51. Teede HJ, Hutchison S, Zoungas S, Meyer C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine. 2006 Aug;30(1):45-53.
  52. Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000 Apr;15(4):785-9.
  53. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003 Jun;88(6):2562-8.
  54. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Nov;89(11):5454-61.
  55. Glueck CJ, Morrison JA, Goldenberg N, Wang P. Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism. 2009 May;58(5):714-21.
  56. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992 Aug;37(2):119-25.
  57. Vaggopoulos V, Trakakis E, Chrelias C, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with Insulin Resistance. J Endocrinol Invest. 2012 Nov 27.
  58. Huang G, Coviello A. Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2012 Dec;19(6):512-9.
  59. Pedroso DC, Melo AS, Carolo AL, Vieira CS, Rosa e Silva AC, dos Reis RM. Frequency and risk factors for metabolic syndrome in adolescents and adults women with polycystic ovary syndrome. Rev Bras Ginecol Obstet. 2012 Aug;34(8):357-61.
  60. Chen W, Lu F, Liu SJ, et al. Cancer risk and key components of metabolic syndrome: a population-based prospective cohort study in Chinese. Chin Med J (Engl). 2012 Feb;125(3):481-5.
  61. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012 2012:413782.
  62. Sella T, Chodick G, Barchana M, et al. Gestational diabetes and risk of incident primary cancer: a large historical cohort study in Israel. Cancer Causes Control. 2011 Nov;22(11):1513-20.
  63. Sieri S, Muti P, Claudia A, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012 Feb 15;130(4):921-9.
  64. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007 Mar;30(3):561-7.
  65. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011 Aug;22(8):1163-71.
  66. Available at: http://www.cancer.org/cancer/news/lung-cancer-also-affects-nonsmokers. Accessed March 6, 2013.
  67. Available at: http://articles.chicagotribune.com/2012-08-22/lifestyle/sns-201208211500--tms--premhnstr--k-i20120822-20120822_1_lung-cancer-clinical-oncology-cervical-cancer Accessed March 6, 2013
  68. Available at: http://www.who.int/tobacco/framework/WHO_FCTC_english.pdf. Accessed February 4, 2013.
  69. Available at: http://www.surgeongeneral.gov/library/reports/secondhandsmoke/index.html. Accessed February 4, 2013.
  70. Available at: http://monographs.iarc.fr/ENG/Monographs/vol83/index.php. Accessed February 4, 2013.
  71. Brennan P, Buffler PA, Reynolds P, et al. Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies. Int J Cancer. 2004 Mar;109(1):125-31.
  72. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008 Sep 1;123(5):1133-40.
  73. Zhou B, Liu J, Wang ZM, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One. 2012;7(8):e43075.
  74. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst. 2011 Jul 20;103(14):1112-22.
  75. Dankner R, Shanik MH, Keinan-Boker L, Cohen C, Chetrit A. Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study. Diabetes Care. 2012 Jul;35(7):1538-43.
  76. Luo J, Chen YJ, Chang LJ. Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2012 May;76(2):242-7.
  77. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, et al. Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res. 2012 2012:732027.
  78. Stebbing J, Sharma A, North B, et al. A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumour responses to chemotherapy. Ann Oncol. 2012 Apr;23(4):860-6.
  79. Erickson K, Patterson RE, Flatt SW, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011 Jan 1;29(1):54-60.
  80. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006 Jul 1;119(1):236-8.
  81. J. Goodwin M, Ennis KI, Pritchard, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42–51.
  82. Railo J, Smitten KV, Pekonen F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer. 1994 Part A; 30(3):307–11.
  83. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Research. 1997;57(15):3079–83.
  84. Hickish T, Astras G, Thomas P, et al. Glucose intolerance during adjuvant chemotherapy for breast cancer. J Nat Cancer Inst. 2009;101(7):537.
  85. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 Dec;49(12):2063-9.
  86. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999;58 Suppl 1:31-9; discussion 75-82.
  87. Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. J Agric Food Chem. 2010 Apr 14;58(7):4141-4.
  88. Nagendran MV. Effect of green coffee bean extract (GCE), high in chlorogenic acids, on glucose metabolism. Poster presentation number: 45-LB-P. Obesity 2011, the 29th Annual Scientific Meeting of the Obesity Society. Orlando, Florida. October 1-5, 2011.
  89. Available at: http://vtcardsfellows.com/pdf/Guidelines/Reviewarticles/ Mechanism_of_Diease_Atherosclerosis_and_CAD.pdf. Accessed February 4, 2013.
  90. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other mark-ers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 342:836-43.
  91. Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res. 2002 Jan;52(1):1-23.
  92. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, and Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–21.
  93. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biosci. 2008;13:5094-107.
  94. Sgambato A, Cittadini A. Inflammation and cancer: a multifaceted link. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):263-8.
  95. Schmidt R, Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study, Ann Neurol. 2002 Aug;52(2):168-74.
  96. Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem. 2009 Mar;108(6):1343-59.
  97. Schram MT, Euser SM, de Craen AJ, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007 May;55(5):708-16.
  98. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011 Jul-Aug;48(4):155-70.
  99. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011 Jun 3;13(3):R55.
  100. Imai N, Kinoshita A, Onoda H, et al. Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma. Clin Transl Oncol. 2012 Dec 21. [Epub ahead of print]
  101. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009 Jul 20;27(21):3437-44.
  102. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009 May 1;27(13):2217-24.
  103. Heikkilä K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009 Feb;20(1):15-26.
  104. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol. 2006 Nov 20;24(33):5216-22.
  105. Il’yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8.
  106. Shen L, Li ZM, Lu S. Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2011 Jun;33(6):442-6.
  107. Alifano M, Falcoz PE, Seegers V, et al. Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. Thorac Cardiovasc Surg. 2011 Nov;142(5):1161-7.
  108. Chaturvedi AK, Caporaso NE, Katki HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol. 2010 Jun 1;28(16):2719-26.
  109. Alfano CM, Imayama I, Neuhouser ML, et al. Fatigue, inflammation, and ω-3 and ω-6 fatty acid intake among breast cancer survivors. J Clin Oncol. 2012 Apr 20;30(12):1280-7.
  110. Ko YJ, Kwon YM, Kim KH, et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2076-86.
  111. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and cancer. J Epidemiol. 2011;21(3):161-8.
  112. Woo Y, Hyung WJ, Obama K, et al. Elevated high-sensitivity C-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence. J Surg Oncol. 2012 Mar 15;105(4):405-9.
  113. Ridker PM. Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke. Circulation. 2003 Sep 23;108(12):e81-5.